Phathom Pharmaceuticals has spent 2026 in the spotlight for very different reasons. On one side, Q3 results showed higher revenue and a smaller loss, and management reaffirmed a target for operating profitability in 2026. For Phathom Pharmaceuticals shareholders, the loss from the start of the year was 63.5%, including dividends. If you were weighing a fresh position after that drop, would the improving cost profile and new VOQUEZNA data justify taking that risk? This theme extends beyond...
Phathom Pharmaceuticals (PHAT) said Friday that BDR Pharmaceuticals International has sued the US Fo
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDTFLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 29, 2026, to report its third quarter 2026 financial results and provide a business update. A live webcast and a
Detailed price information for Phathom Pharmaceuticals Inc (PHAT-Q) from The Globe and Mail including charting and trades.
Phathom Pharmaceuticals (PHAT) has an average rating of Buy and mean price target of $23.70, accordi
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference in New York, NYDate: Wednesday, September 9, 2026Fireside Chat: 10:55 am EDTManagement to par
This is the newest page. Registered accounts read further back.